News

Deal Announcements

4s3 Bioscience Banks $20 Million Venture Capital

Wednesday, March 7, 2012 5:30:00 AM PDT | VentureDeal Staff
Medford, Massachusetts  --  Genetic biotechnology company 4s3 Bioscience has secured $20 million in series A round of venture capital investment.

4s3 is developing therapies for orphan genetic muscle diseases by utilizing an antibody-based targeting system.

KLP Enterprises made the investment.
 
The company said it would use the funding to support the continued development of its proprietary antibody technology.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1